BioCentury | Jul 13, 2019
Product Development
Why Merck is in infectious disease for the long haul
...to AureoGen Biosciences Inc.’s preclinical aureobasidin A derivatives to treat infectious disease, and partnered with OpGen Inc....
...Services (CMS), Baltimore, Md. Harvard University, Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. OpGen Inc....
...Services (CMS), Baltimore, Md. Harvard University, Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. OpGen Inc....